dr. kim on the keynote-189 trial in metastatic nsclc
Published 4 years ago • 222 plays • Length 1:55Download video MP4
Download video MP3
Similar videos
-
10:32
the keynote-189 trial for untreated metastatic nonsquamous nsclc
-
10:34
the keynote-189 trial for untreated metastatic nonsquamous nsclc
-
2:21
dr. kim on clinical trial eligibility criteria in lung cancer
-
4:53
chemo-immunotherapy in nsclc: the keynote-189 trial
-
1:08
dr. stinchcombe on the keynote-189 trial in lung cancer
-
1:55
dr. rodriguez-abreu on the final analysis of the keynote-189 trial in nsclc
-
2:25
dr. gadgeel on updated keynote-189 data in nsclc
-
1:42
dr. kim discusses the impact of the pacific trial in nsclc
-
4:21
optimizing use of the keynote-189 regimen in mnsclc
-
0:59
dr. rodriguez-abreu on updated results from the keynote-189 trial in nsclc
-
2:57
keynote 189: targeting nsclc patients with brain and liver metastases
-
2:11
dr. kim discusses data from the impower150 trial in nonsquamous nsclc
-
5:42
keynote-189: chemotherapy and pembrolizumab in mnsclc
-
3:03
keynote-189 update: 4-year follow-up of fl pembro chemo metastatic nsclc
-
1:53
dr. spigel on pembrolizumab/chemo combo in first-line nsclc
-
2:02
keynote-189: chemo plus pembrolizumab for nsclc
-
5:43
advanced-stage nsclc: keynote-189’s role in treatment
-
6:32
keynote-189: clinical implications in patients with less than 1% tumor pd-l1 expression (bmic-033)
-
1:28
dr. kim on the importance of biomarker testing for lung cancer